|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Hamilton Health Sciences |
|---|---|
| Information provided by: | McMaster University |
| ClinicalTrials.gov Identifier: | NCT00157638 |
Purpose
Recent health policy documents have endorsed an integrated model of collaboration between pharmacists and physicians in primary care. The integration of pharmacists into primary care has been identified as a priority for primary health care reform in Canada. However, the best way to do this has not been demonstrated or evaluated. This demonstration project shows the various ways in which pharmacists can be trained and integrated into different family practice settings, the processes and costs associated with doing this, and the outcomes observed. The main hypothesis is that pharmacist integration into family practice will optimize medication use, clinical care and clinical outcomes. This information provides policy makers with necessary information about collaboration between pharmacists and family physicians for their overall goal of reforming the delivery of primary health care to the population.
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetes Hypertension Hyperlipidemia Constipation Pain |
Behavioral: integration of pharmacist into primary care Drug: optimizing therapeutic treatments Behavioral: optimizing processes of care |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Educational/Counseling/Training, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | Optimizing Drug Therapy in Primary Care: Integrating Pharmacists With Ontario Family Physician Group Practices. |
| Estimated Enrollment: | 1400 |
| Study Start Date: | February 2004 |
| Estimated Study Completion Date: | July 2006 |
The overall goal of IMPACT was to improve patient outcomes by optimizing drug therapy through a community practice model that integrates pharmacists into family practices.
This multi-site demonstration project involved 7 pharmacists, approximately 70 physicians and approximately 150,000 patients. Within each practice site, a pharmacist with special clinical training worked 2.5 days per week for 2 years and coordinated a multifaceted intervention aimed at optimizing drug therapy to improve patient outcomes (blood pressure, cholesterol, diabetes, pain control, constipation, etc.) The integrated pharmacist conducted patient assessments for medication problems, optimized office system medication management (e.g. develop process for handling of medication samples), and provided education (academic detailing ) focussed on key therapeutic areas. Pharmacists were provided with ongoing support from a training and mentorship program and the services of the Ontario Pharmacists’ Association Drug Information Centre.
The family physicians and other members of the practice worked closely with the pharmacist in implementing these strategic interventions. Family physicians from a range of practice models (Ontario Family Health Networks, Primary Care Networks, and other types of family physician group practices) participated in this project.
Quantitative and qualitative methods were used to evaluate the process of integration, pharmacist service uptake, drug-related patient outcomes, and the costs associated with program implementation for sustainability. The integration of the physicians and pharmacists at the practice sites were evaluated with the aim of generating a practical and transferable practice model. The main hypothesis was that pharmacist integration into family practice will optimize medication use, clinical care and clinical outcomes.
Eligibility| Ages Eligible for Study: | 65 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
65 + years and any two of the following:
Exclusion Criteria:
Contacts and Locations| Canada, Ontario | |
| McMaster University | |
| Hamilton, Ontario, Canada, L8N 1G6 | |
| University of Ottawa | |
| Ottawa, Ontario, Canada, K1N 5C8 | |
| University of Toronto | |
| Toronto, Ontario, Canada, M5S 2S2 | |
| Principal Investigator: | Lisa Dolovich, PharmD, MSc | McMaster University |
| Principal Investigator: | Kevin Pottie, MD | University of Ottawa, Ottawa ON |
| Principal Investigator: | Janusz Kaczorowski, PhD | McMaster University |
| Principal Investigator: | Barbara Farrell, PharmD | Elisabeth Bruyere Research Institute, Ottawa, ON |
More Information
| Study ID Numbers: | G03-02671 |
| Study First Received: | September 8, 2005 |
| Last Updated: | September 8, 2006 |
| ClinicalTrials.gov Identifier: | NCT00157638 History of Changes |
| Health Authority: | Canada: Health Canada |
|
pharmacist physician primary care collaboration therapeutics |
|
Signs and Symptoms Metabolic Diseases Hyperlipidemias Signs and Symptoms, Digestive Vascular Diseases Constipation |
Diabetes Mellitus Pain Metabolic Disorder Dyslipidemias Lipid Metabolism Disorders Hypertension |
|
Signs and Symptoms Metabolic Diseases Hyperlipidemias Signs and Symptoms, Digestive Vascular Diseases |
Constipation Cardiovascular Diseases Dyslipidemias Lipid Metabolism Disorders Hypertension |
